BET Bromodomain Targeting by NSAIDs : Structural, Biophysical, and Computational Insights
Proteins: Structure, Function, and Bioinformatics · 2026-12 · 94 (12) · 1965-1989
DOI: 10.1002/prot.70154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proteins: Structure, Function, and Bioinformatics, online erschienen am 15.07.2026. Verfasst von Ashok Sridhar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biophysics, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India. Hauptthemen laut MEDLINE: Anti-Inflammatory Agents, Non-Steroidal, Sulfonamides, Transcription Factors, Nuclear Proteins. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Indian Council of Medical Research, Department of Science and Technology, Ministry of Science and Technology, India, Department of IT, BT & ST.
Abstract (Originalsprache)
The bromodomain and extra‐terminal (BET) family of proteins, which regulate chromatin function, is an established potential drug target for treating major diseases such as cancer and inflammatory conditions. There is significant research focused on developing new BET inhibitors with innovative molecular structures to target and modulate the epigenetic mechanisms underlying major diseases, including cancer. Herein, we present the crystal structures of the second bromodomain (BD2) of hBRD2 in complex with the FDA‐approved drugs, mefenamic acid (ID8) and nimesulide (NIM), and that of the first bromodomain (BD1) of hBRD4 in complex with nimesulide (NIM). Quantitative binding assays by surface plasmon resonance (SPR) confirmed the substantial binding of these drug molecules to the hBRD2 and hBRD4 bromodomains. Using these crystal structures, a series of ID8 and NIM derivatives with improved affinity relative to the parent compounds was designed and evaluated using SeeSAR (BioSolveIT GmbH). Moreover, molecular dynamics simulations were performed on the selected derivatives of ID8 and NIM against these bromodomains and confirmed the stability of these derivatives' binding throughout the simulations. We propose that the derivatives of the aforementioned parent molecules may be potential inhibitors of the function of hBRD2 and hBRD4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biophysics, National Institute of Mental Health and Neurosciences (NIMHANS), Bengaluru, India.
- Institute of Bioinformatics and Applied Biotechnology (IBAB), Bengaluru, India.
ORCID-Profile: Saravanamuthu Thiyagarajan
Förderung
- Indian Council of Medical Research
- Department of Science and Technology, Ministry of Science and Technology, India
- Department of IT, BT & ST
- Government of Karnataka to IBAB
Zitieren
APA
Sridhar, A., Kandhasami, N., Mathur, S., Krishnappa, G., Thiyagarajan, S., & Padmanabhan, B. (2026). BET Bromodomain Targeting by NSAIDs : Structural, Biophysical, and Computational Insights. Proteins: Structure, Function, and Bioinformatics, 94(12), 1965-1989. https://doi.org/10.1002/prot.70154
Vancouver
Sridhar A, Kandhasami N, Mathur S, Krishnappa G, Thiyagarajan S, Padmanabhan B. BET Bromodomain Targeting by NSAIDs : Structural, Biophysical, and Computational Insights. Proteins: Structure, Function, and Bioinformatics. 2026;94(12):1965-1989. doi:10.1002/prot.70154
BibTeX
@article{Sridhar2026,
author = {Sridhar, Ashok and Kandhasami, Nivetha and Mathur, Shruti and Krishnappa, Gopinatha and Thiyagarajan, Saravanamuthu and Padmanabhan, Balasundaram},
title = {BET Bromodomain Targeting by NSAIDs : Structural, Biophysical, and Computational Insights},
journal = {Proteins: Structure, Function, and Bioinformatics},
year = {2026},
volume = {94},
number = {12},
pages = {1965--1989},
doi = {10.1002/prot.70154}
}
EUVIMED